Amazon’s diagnostics entry no threat to hospital labs: Jupiter Life Line CEO

Published : Jul 01, 2025, 12:50 PM IST
https://stocktwits.com/news-articles/markets/equity/amazons-diagnostics-entry-no-threat-to-hospital-labs-jupiter-life-line-ceo-19629494/chFWTYGRRNi

Synopsis

Jupiter Life Line Hospitals currently operates three hospitals with around 1,200 beds and plans to double that to 2,500 beds over the next three to four years.

Ankit Thakker, Executive Director and CEO of Jupiter Life Line Hospitals, believes that Amazon's entry into the diagnostics space is unlikely to impact hospital labs. “For hospital labs, it is predominantly captive usage. I don't think any of the hospital labs rely too much on community footfall,” he said.

Amazon has launched its at-home diagnostics service in India, expanding its healthcare offerings to include lab test bookings through its app. This follows the earlier launches of Amazon Pharmacy and Amazon Clinic. The new service, in partnership with Orange Health Labs, will operate in six cities—Bengaluru, Delhi, Gurgaon, Noida, Mumbai, and Hyderabad—covering over 450 pin codes and running daily from 6 am to 9 pm.



On pricing, Thakker said it is “still early days” to assess the implications. It remains to be seen whether Amazon will act as a marketplace or run labs directly.

Jupiter Life Line Hospitals currently operates three hospitals with around 1,200 beds and plans to double that to 2,500 beds over the next three to four years. The expansion includes new 500-bed hospitals in Dombivli (Palava) and Pune, and a 300-bed facility in Mira-Bhayandar. Most of this growth will be funded internally.

Also Read | Jupiter Life Line plans three new hospitals, eyes more complex surgeries in Indore

Breaking down current operations, Thakker explained, Thane hospital is mature, with average revenue per occupied bed (ARPOB) expected to rise with inflation, and Pune has room for occupancy growth from the current mid-60% levels to above 70%. Indore added 80 beds this year and will see benefits from price revisions and case mix improvements.

On digital and pharmacy verticals, Jupiter has no immediate plans for spin-offs. “We want to continue focusing on the healthcare business,” Thakker said.

As for inorganic growth, the company remains focused on Western India and prefers greenfield projects. However, the company is open to looking at interesting acquisition opportunities, he said.

Also Read | Amazon’s diagnostics entry a wake-up call for the sector, says Narayana CFO

Jupiter has no significant international focus and derives minimal revenue from overseas patients. Its model is centred around serving local communities within a 30 to 40-minute radius of each hospital.

Insurance now accounts for 55% of Jupiter's revenue. He added that both retail and group insurance are expected to grow substantially in the coming years.

The company, with a market capitalisation of ₹9,859.49 crore, has seen its stock rise over 16% in the past year.

For the full interview, watch the accompanying video

Catch all the latest updates from the stock market here

PREV

Recommended Stories

CRH, Carvana And Comfort Systems Jump After-Hours As S&P 500 Changes Shake Up Winners And Losers
Northrop Grumman Says Test Data From New Rocket Motor Built In Less Than A Year Looks ‘Promising’